Protocol Ledger

NCT05566795 · Phase III · ACTIVE NOT RECRUITING

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Interventional Phase III clinical trial protocol NCT05566795 sponsored by Day One Biopharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-27 Enrollment: 418 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05566795
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)418 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05566795
Protocol FieldVerified Registry Value
NCT IdentifierNCT05566795
Consolidated Lead SponsorDay One Biopharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment418 participants (ACTUAL)
Registered Start Date2023-02-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI